{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Valencia-Sandonis C"],"funding":["Ministry of Science, Innovation and Universities","University of Valladolid","Junta de Castilla y León and the European Social Fund"],"pagination":["8918"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12469960"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["26(18)"],"pubmed_abstract":["Dry eye disease (DED) is a prevalent condition characterized by ocular surface inflammation and pain. This study evaluated the long-term progression of DED by analyzing clinical and molecular status, considering the impact of chronic ocular pain. Patients with DED were evaluated at two visits (V1 and V2) separated by at least two years. Evaluations included validated symptom questionnaires alongside slit-lamp examination, corneal sensitivity testing, and sub-basal nerve plexus analysis. Basal tear samples were collected for multiplex quantification of 20 cytokines and substance P (SP), and conjunctival cells were obtained to analyze 25 genes and 12 microRNAs (miRNA). Based on the presence or absence of chronic ocular pain, patients were then divided into two groups. Patients improved in DE"],"journal":["International journal of molecular sciences"],"pubmed_title":["Long-Term Clinical and Molecular Changes in Dry Eye Disease and Chronic Ocular Pain."],"pmcid":["PMC12469960"],"funding_grant_id":["SAF-2016-77080-P","predoctoral grant 2020","EDU/1192/2020","FPU17/02715"],"pubmed_authors":["Valencia-Sandonis C","Valencia-Nieto L","Vazquez A","Novo-Diez A","Blanco-Vazquez M","Calonge M","Calderon-Garcia AA","Gonzalez-Garcia MJ","Enriquez-de-Salamanca A"],"additional_accession":[]},"is_claimable":false,"name":"Long-Term Clinical and Molecular Changes in Dry Eye Disease and Chronic Ocular Pain.","description":"Dry eye disease (DED) is a prevalent condition characterized by ocular surface inflammation and pain. This study evaluated the long-term progression of DED by analyzing clinical and molecular status, considering the impact of chronic ocular pain. Patients with DED were evaluated at two visits (V1 and V2) separated by at least two years. Evaluations included validated symptom questionnaires alongside slit-lamp examination, corneal sensitivity testing, and sub-basal nerve plexus analysis. Basal tear samples were collected for multiplex quantification of 20 cytokines and substance P (SP), and conjunctival cells were obtained to analyze 25 genes and 12 microRNAs (miRNA). Based on the presence or absence of chronic ocular pain, patients were then divided into two groups. Patients improved in DE","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-05-01T03:21:54.71Z","creation":"2026-05-01T03:11:27.303Z"},"accession":"S-EPMC12469960","cross_references":{"pubmed":["41009486"],"doi":["10.3390/ijms26188918"]}}